FolioLanternBeta
BLTEBelite Bio, Inc

Nathan Mata

Chief Scientific Officer at Belite Bio, Inc, as of May 8, 2026Sold $2.7M of stock since March 18, 2026: 100% under a disclosed plan.

Updated Oct 16, 2026 from SEC filings · covers Mar 18, 2026 to Oct 16, 2026

Officers and directors of non-US companies only began filing Forms 3 and 4 on March 18, 2026 (a new SEC rule), so this page covers the period since then. Their 10% holders still do not file. The SEC rule

17K
shares sold, since March 18, 2026
17
days with sales
$170K
largest single day, Apr 22, 2026
1
company filed for

Share of stake sold and shares held at Belite Bio, Inc are being verified and not shown yet. Why

Selling by month

Mar 2026 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planOne dollar scale for every month; the tallest bar is labeled
MarApr 2026: $2.0M under a disclosed plan$2.0MAprMay 2026: $723K under a disclosed planMayJunJulAugSepOct

Pattern

What the filings show, since March 18, 2026. Nothing here rates or predicts.

Roles from filings

Every company we track where this person has filed, newest filing first.

CompanyTitleFirst filingLatest filing
Belite Bio, Inc (BLTE)Chief Scientific OfficerMar 18, 2026May 8, 2026

Recent filings

The last 5 days with transactions, newest first, one line per trade date. Each number links to an SEC filing.

This page shows only what this person reported on SEC ownership filings. See the methodology. Spotted something wrong? Report an error.